CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性抗体的临床开发：血液系统恶性肿瘤中的综述、进展与挑战
英文原题：Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies.
查看英文原题
Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
单克隆抗体（mAb）、免疫检查点抑制剂（ICI）和嵌合抗原受体（CAR）T 细胞疗法等精准治疗已改变癌症治疗格局。其中，双特异性抗体（bsAb）因可同时靶向两种不同分子抗原而日益受到关注，其目标是募集 T 细胞以绕过肿瘤免疫逃逸机制并导致肿瘤细胞溶解。目前，美国、欧洲和日本已批准多种用于血液系统恶性肿瘤的 bsAb，其中多数通过 CD3 重定向 T 细胞，但其他免疫激活机制也正在探索。本章综述血液系统恶性肿瘤中处于临床开发阶段的 bsAb，介绍其基本结构和作用机制，并总结当前临床研究中开发最成熟的 bsAb 的疗效与安全性结果。
展开英文摘要原文
Precision therapies such as monoclonal antibodies (mAbs), immune-checkpoint inhibitors (ICIs), and chimeric antigen receptor T (CAR T)-cell therapies have revolutionized the treatment of cancer. Of these, bispecific antibodies (bsAbs) are gaining attention for their ability to simultaneously target two distinct molecular antigens, aimed at engaging T cells to circumvent cancer immune evasion mechanisms, resulting in tumor cytolysis.
Several bsAbs have now been approved in the United States, Europe, and Japan for the treatment of hematological malignancies, most of which are CD3-redirecting bsAbs, although other immune-activating mechanisms are also being explored. This chapter reviews bsAbs in clinical development for hematological malignancies, their basic structure and mechanism of action, and efficacy and safety results of the most advanced bsAbs under clinical investigation.
论文信息
- 作者
- Saitoh A
- 单位
- Hematology Department, Oncology, Medical Affairs, Johnson & Johnson, Tokyo, Japan. asaitoh@its.jnj.com.Japan
- 文献类型
- 综述
- 期刊
- Methods in molecular biology (Clifton, N.J.)2026
- 原文标识
- PubMed 42108355 · DOI 10.1007/978-1-0716-5037-0_17